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A genetic approach for studying the role of thromboxane A2 in the
kidney. Thromboxane A2 (TxA2) has been implicated in a number
of processes in normal kidney physiology and as a mechanism for
injury in renal disease. TxA2 is a biologically active derivative of
arachidonic acid and has potent vasoconstrictive and platelet-
activation functions. Its actions are mediated by binding to specific
G-protein-associated receptors designated TP receptors. There
are at least two isoforms of the human TP receptor, and pharma-
cological evidence suggests TP receptor heterogeneity in other
species. TP receptors are located in the renal cortex, and there
may also be TxA2 binding sites in the medulla. TP receptors are
involved in some normal functions of the kidney, and there is
considerable evidence that TP receptors may mediate renal
damage in disease states. To assess directly the role of the TxA2 in
normal kidney function and in murine models of human disease,
we have used gene targeting to eliminate expression of the TP
receptor in mice.
The lipid mediator thromboxane A2 (TxA2) has a num-
ber of biological effects that contribute to both normal
physiological responses and to the pathogenesis of disease
states. TxA2 stimulates vascular smooth muscle contraction
and promotes platelet aggregation, resulting in potent
hemodynamic and procoagulant effects that are held to
play a role in cardiovascular diseases [1]. In addition, TxA2
is a potent bronchoconstrictor and proinflammatory agent
that may play a role in asthma and other reactive airway
diseases [2]. In the kidney, TxA2 seems to be involved in
normal regulation of renal hemodynamics and sodium
excretion and also may act as a final common pathway for
kidney injury in a variety of diseases. Investigations of the
biology of TxA2 have been complicated by the evanescence
of the compound, which is rapidly hydrolyzed to an inactive
form in aqueous solutions. Definitions of in vivo roles for
TxA2 have relied primarily on pharmacological inhibitors
of thromboxane synthase or TP receptor antagonists. The
cloning of the TP receptor and the enzymes involved in
TxA2 synthesis has provided additional tools and ap-
proaches for understanding the functions of TxA2 in nor-
mal physiology and in disease states. In this review, we
discuss the role of TxA2 in the kidney and detail the
creation of new genetic tools that should allow direct
examination of the contribution of TxA2 to kidney ho-
meostasis and its role in the pathogenesis of the kidney in
various renal disease models.
THROMBOXANE A2 BIOSYNTHESIS
TxA2 is produced by the sequential enzymatic metabo-
lism of arachidonic acid through the cyclooxygenase or
prostaglandin H (PGH) synthase pathway [3]. Arachidonic
acid is released from phospholipids in the cell membrane
by the actions of lipases, including phospholipases A and C,
which are under hormonal control [4, 5]. Free arachidonic
acid is sequentially converted to prostaglandin (PG) G2 and
then PGH2 by the cyclooxygenase and peroxidase actions of
cyclooxygenase (PGH synthase) enzymes 1 and 2 [6]. PGH2
is converted to active TxA2 by the actions of thromboxane
synthase. Thromboxane synthase is one of the p450 family
of membrane-bound proteins. Although thromboxane syn-
thase shares spectoral characteristics of the cytochrome
p450s, it lacks monooxygenase activity and does not require
reductase to initiate the reaction [7]. Under physiological
conditions, TxA2 is rapidly hydrolyzed (t1/2 5 30 seconds)
to TxB2, which is stable but physiologically inactive. Thus,
the effects of TxA2 are largely confined to tissues near the
source of its production [8]. Due to its stability, measure-
ment of TxB2 has been a useful marker for assessing the
production of TxA2 in vivo [9]. Although a number of
thromboxane metabolites are found in urine, urinary excre-
tion of unmetabolized, native TxB2 appears to directly
reflect TxA2 production by the kidney [10].
THROMBOXANE RECEPTORS
Actions of TxA2 are mediated through binding to cell-
surface receptors. TP receptors from human, rat, and
mouse have been cloned and belong to the large family of
G-protein—coupled receptors [11–14]. TP receptors are
expressed in a number of cell types, including platelets,
lung, kidney, spleen, and placenta [11, 13, 15]. Although
the TP receptors cloned to date demonstrate substan-
tial homology, earlier pharmacological studies suggested
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heterogeneity of function and agonist binding characteris-
tics [16–19]. In mesangial cells, vascular smooth muscle
cells, and platelets, activation of the TP receptor is associ-
ated with rapid increases in intracellular calcium that are
dependent, at least in part, on phospholipase C [5, 18, 20,
21]. In macrophages, however, the TP receptor may be
linked to adenyl cyclase [22]. A structural basis for these
differences in second-messenger coupling and ligand-bind-
ing affinities is not clear. Although there might be different
TP receptor isoforms encoded by distinct genes, only a
single TP receptor gene has been identified to date.
Another possible mechanism that could explain these
biochemical differences is that alternative splicing of
mRNA, as described for the PGE2 receptor [23], might
generate various receptor isoforms. Two isoforms of the
human TP receptor produced by alternative splicing, which
results in a difference in the carboxy-terminal portion of
the receptor, have been identified [24]. Using reverse
transcription-polymerase chain reaction (RT-PCR), Ray-
chowdhury et al have suggested that the two isoforms of the
human TP receptor have unique expression patterns, with
one isoform expressed in platelets and the other in endo-
thelium [24]. However, recently, Hirata et al have shown
that both isoforms are present in human platelets [25]. The
two isoforms share a similar ability to activate phospho-
lipase C but differ in their agonist-binding characteristics
and in their actions on adenyl cyclase.
THROMBOXANE RECEPTORS IN THE KIDNEY
Defining the distribution and regulation of renal TP
receptors is an essential template for understanding the
physiological role of thromboxane in the kidney. Until
recently, a precise characterization of the cellular distribu-
tion of TP receptors in the kidney had been somewhat
elusive. Through radioligand studies, TP-binding sites had
been demonstrated on isolated glomeruli in rats [19, 26, 27]
and mice [28], as well as on rat mesangial cells in culture
[20, 29, 30]. Using in situ hybridization, Abe et al localized
TP receptor mRNA expression to glomerular cells, smooth
muscle cells of the renal vasculature, and transitional cells
of the renal pelvis [12]. In a subsequent study using
immunostaining with an anti-TP receptor antibody, tubular
localization of TP receptors was also suggested [31].
Our laboratory has utilized receptor autoradiography to
identify and localize thromboxane-binding sites in the
kidney using the high-affinity TxA2 agonist, [
125I]-BOP [32].
This technique has the advantage of localizing functional
TP receptors, regardless of the nature of the gene products
involved. We have found distinct [125I]-BOP—binding sites
in renal cortex, especially in glomeruli, and arteries and
arterioles. Unexpectedly, we also found diffuse I-BOP
binding in the renal medulla. Scatchard analysis showed
detect both high (Kd 5 262 6 16 pM) and lower (Kd 5
8.2 6 2.2 nM) affinity binding sites, with a predominance of
the lower affinity sites in renal medulla. These sites do not
appear to represent receptor isoforms arising from alter-
native splicing of the TP receptor mRNA and thus may
represent a novel TP receptor or an alternative affinity
state for the previously characterized renal TP receptors.
DIRECT EFFECTS OF THROMBOXANE A2 IN THE
KIDNEY
TxA2 has a number of biological effects that could
contribute to its role both in normal kidney physiology and
as a mediator of kidney dysfunction and injury. For exam-
ple, TxA2 causes marked renal vasoconstriction [33], and
thus enhanced renal TxA2 production should reduce renal
blood flow and glomerular filtration rate. TxA2 also stim-
ulates mesangial cell contraction and thus may have direct
effects on glomerular filtration and proteinuria that are
independent of its effects on renal vasculature [34]. Welch
and associates found that pressor responses to infusion of
angiotensin II are blunted in the presence of TP receptor
antagonists [35, 36], suggesting that TxA2 may also modu-
late the hemodynamic effects of other hormonal mediators
in the kidney.
TxA2 may also regulate epithelial and reabsorptive func-
tions in the kidney. For example, infusion of the TP
receptor agonist U46619 alters Cl reabsorption in medul-
lary nephron segments [37]. Also, Burch and Halushka
have shown that thromboxane alters vasopressin-stimulated
water flow in toad bladder, a model of collecting duct
epithelium [38]. A role for TxA2 in regulating tubuloglo-
merular feedback (TGF) responses has also been suggested
[39]. In these experiments, the TP receptor antagonist SQ
29,548 reduced TGF responses.
THROMBOXANE A2 IN KIDNEY DISEASES
Enhanced production or actions of TxA2 have been
described in a number of kidney diseases that vary widely in
their pathogenesis, including both inflammatory and non-
inflammatory processes. For example, patients with diabe-
tes have increased levels of urinary TxB2 [40]. Furthermore,
in rodent models of diabetic nephropathy, TxA2 synthesis
inhibition reduces renal damage [41–43]. Cyclosporine
nephrotoxicity is another noninflammatory renal disease in
which TxA2 appears to play a pathogenetic role. Renal
TxA2 production is enhanced in rats with cyclosporine
nephrotoxicity [44], and TP receptor antagonists improve
kidney function in rats models [45–47] and in humans [48]
with cyclosporine-induced renal dysfunction.
TxA2 has also been implicated in various inflammatory
or immunological renal diseases. Increased urinary excre-
tion of thromboxane metabolites has been demonstrated
during acute rejection episodes in human kidney transplant
patients [49, 50]. Similarly, enhanced thromboxane produc-
tion has been demonstrated in the rejection of renal
allografts in the rat, and TxA2-synthase inhibitors improve
renal function and limit renal pathological changes [51–53].
In the MRL-lpr model of autoimmune glomerulonephritis,
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we have also found that enhanced production of TxA2
causes renal hemodynamic dysfunction, promotes glomer-
ular immune complex formation, and modulates glomeru-
lar inflammation [54]. The use of either TP receptor
antagonists or TxA2 synthase inhibitors significantly re-
duces the severity of the kidney disease in autoimmune
mice, indicating a key role for TxA2 in this disease that
resembles lupus nephritis in humans [55–57]. Taken to-
gether and coupled with the known actions of TxA2 in the
kidney, these observations suggest that thromboxane may
function as a final common pathway that mediates renal
injury in a wide range of diseases.
In addition to direct effects of thromboxane in promot-
ing kidney dysfunction and injury, thromboxane also has
effects on the immune system that may contribute indi-
rectly to the pathogenesis of kidney disease. For example,
TP receptor expression is high in the thymus, most prom-
inently in immature thymocyte populations [58]. Stimula-
tion of TP receptors on these cells induces programmed
cell death, suggesting that TP receptors on thymocytes
might play a role in negative selection of maturing T
lymphocytes. Remuzzi et al have shown that inhibition of
TP receptors impairs the development of tolerance to
kidney allografts, further supporting a functional role for
thymic TP receptors in T-cell development [59]. TxA2 may
also directly promote and modulate cytotoxic T-cell func-
tion and allospecific proliferation [60, 61].
THROMBOXANE RECEPTOR GENE TARGETING
Using RT-PCR, we prepared a 438-bp partial cDNA
probe specific for the mouse TP receptor from mouse lung
RNA using primers based on the published sequence for
the mouse TP receptor cDNA [13]. This probe was used to
screen a BamHI digested genomic library constructed in
the lambda Dash II phage vector using DNA isolated from
the mouse embryonic stem cell line E14tg2a. Three iden-
tical clones were obtained that were approximately 12 kb in
size. Oligonucleotide probes made from different regions
of the TP receptor cDNA hybridized with the clone,
suggesting that it contains the entire coding region. This
was confirmed by sequencing. In addition to the coding
region, the clone contains approximately 3 kb of 59 and 5 kb
of 39 flanking DNA. To facilitate the study of TP receptors
in vivo, we used this clone to construct a targeting vector to
produce mice lacking TP receptors, using homologous
recombination in embryonic stem cells. An 8-kb KpnI
fragment containing exons 2 and 3 of the TP receptor and
encompassing all protein coding sequences was subcloned
into pBluescript KS (Stratgene, La Jolla, CA, USA). A
PGK-Neo cassette was inserted into a unique SfiI site,
located near the proximal end of exon 2. The resulting
plasmid was introduced into the HPRT2 embryonic stem
cell line E14tg2a by electroporation, and genomic clones
from G418 resistant colonies were isolated and screened by
Southern blot analysis. We obtained a correctly targeted
cell line and used this cell line to create chimeric mice.
Backcrossing the chimeric mice to B6/D2 mice and subse-
quent intercrossing of heterozygotes yielded mice lacking
functional TP receptors. These mice will be powerful tools
for investigating the actions TxA2 without the complica-
tions associated with pharmacological inhibition studies.
The TP receptor null mutant mice will allow us to access
the role of the TP receptor in kidney homeostasis and in
various induced or genetic renal disease states.
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